Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
Avastin is inexpensive for Macular Degeneration therapy
July 14, 2008
Costly Cancer Drug Offers Hope, but Also a Dilemma | www.nytimes.com
I and many other ophthalmologists around the country use Avastin intravitreally for wet macular degeneration in doses far smaller than those used for systemic cancer. Although it is an "off-label" use of the drug, the cost for using Avastin is 1/6oth of Lucentis, a very similar drug, also made by Genentech, that IS FDA approved for macular degeneration. Yet, Avastin works just as well as Lucentis for far less cost. I am able to get the Avastin for $50 per dose, whereas Lucentis is $3,000 per dose. So, where Avastin is expensive for a small benefit in cancer therapy, it is quite inexpensive and highly effective in the treatment of macular dengeneration.
June 5, 2008
Johnson & Johnson Vision Care Announces First Daily Disposable Silicone Hydrogel at BCLA | www.cltoday.com
Many patients who have irregular astigmatism will find a disposable silicone hydrogel lens to provide good vision with less irritation of the cornea due to protein build up in the lens. This could be a big help to those who may not be LASIK candidates or who are awaiting future Custom LASIK surgery for irregular astigmatism.
Page : 11 to 2 of 2
February 7, 2012
What do the cloud, collaboration and virtualization have in common?
January 27, 2012
Clinical diagnostic acquisitions dominate 2011 top ten list
January 12, 2012
Gene therapy success threatens drugs for hemophilia and rare diseases
December 13, 2011
Medtech M&A activity accelerates in 2011
November 30, 2011